Is Buying Calithera Biosciences Incorporated (NASDAQ:CALA), Having Higher Short Interest a Winning Strategy?

September 17, 2017 - By Adrian Erickson

 Is Buying Calithera Biosciences Incorporated (NASDAQ:CALA), Having Higher Short Interest a Winning Strategy?

Investors sentiment increased to 1.2 in Q4 2016. Its up 0.44, from 0.76 in 2016Q3. It improved, as 9 investors sold Calithera Biosciences Inc shares while 6 reduced holdings. 4 funds opened positions while 14 raised stakes. 5.98 million shares or 0.90% more from 5.92 million shares in 2016Q3 were reported.
Susquehanna International Limited Liability Partnership holds 74,569 shares. The California-based Blackrock Institutional Na has invested 0% in Calithera Biosciences Inc (NASDAQ:CALA). 17,457 were accumulated by Northern. Oxford Asset Mngmt holds 0.01% or 49,490 shares in its portfolio. Vanguard Group Inc has 462,878 shares for 0% of their portfolio. Wells Fargo & Mn holds 0% or 8,520 shares. Blackrock Inv Limited Liability Com reported 2,467 shares. 11,513 were accumulated by Millennium Mgmt Limited Liability. 16,149 were accumulated by Goldman Sachs. Manufacturers Life The holds 0% of its portfolio in Calithera Biosciences Inc (NASDAQ:CALA) for 108 shares. Morgan Stanley stated it has 0% in Calithera Biosciences Inc (NASDAQ:CALA). Tfs Llc accumulated 28,408 shares or 0.02% of the stock. Rbf Cap Ltd Liability Corp has invested 0.01% in Calithera Biosciences Inc (NASDAQ:CALA). California Pub Employees Retirement System accumulated 14,100 shares. Franklin Street Advsr Nc holds 0.07% or 124,580 shares in its portfolio.

The stock of Calithera Biosciences Incorporated (NASDAQ:CALA) registered an increase of 0.03% in short interest. CALA’s total short interest was 2.92M shares in September as published by FINRA. Its up 0.03% from 2.92M shares, reported previously. With 386,200 shares average volume, it will take short sellers 8 days to cover their CALA’s short positions. The short interest to Calithera Biosciences Incorporated’s float is 22.25%.

The stock decreased 0.66% or $0.1 on September 15, reaching $15.05. About 1.01M shares traded or 114.09% up from the average. Calithera Biosciences Inc (NASDAQ:CALA) has risen 278.82% since September 17, 2016 and is uptrending. It has outperformed by 262.12% the S&P500.

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The company has market cap of $533.92 million. The Firm focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It currently has negative earnings. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Calithera Biosciences Inc (NASDAQ:CALA) Ratings Coverage

Among 4 analysts covering Calithera Biosciences (NASDAQ:CALA), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Calithera Biosciences had 8 analyst reports since July 24, 2015 according to SRatingsIntel. The firm has “Neutral” rating given on Tuesday, January 24 by Citigroup. Citigroup initiated the stock with “Sell” rating in Tuesday, October 25 report. H.C. Wainwright maintained it with “Buy” rating and $14 target in Tuesday, March 28 report. The stock of Calithera Biosciences Inc (NASDAQ:CALA) earned “Market Outperform” rating by JMP Securities on Wednesday, March 9. The stock of Calithera Biosciences Inc (NASDAQ:CALA) earned “Buy” rating by H.C. Wainwright on Thursday, January 5. H.C. Wainwright maintained Calithera Biosciences Inc (NASDAQ:CALA) on Monday, June 12 with “Buy” rating. As per Friday, July 24, the company rating was initiated by Citigroup.

More notable recent Calithera Biosciences Inc (NASDAQ:CALA) news were published by: Nasdaq.com which released: “Earnings Estimates Moving Higher for Calithera Biosciences (CALA): Time to Buy?” on September 08, 2017, also Globenewswire.com with their article: “Calithera Biosciences Reports First Quarter 2017 Financial Results and Recent …” published on May 09, 2017, Globenewswire.com published: “Calithera Biosciences to Participate in the Citi 12th Annual Biotech …” on August 30, 2017. More interesting news about Calithera Biosciences Inc (NASDAQ:CALA) were released by: Globenewswire.com and their article: “Incyte and Calithera Biosciences Announce Global Collaboration to Develop and …” published on January 30, 2017 as well as Fool.com‘s news article titled: “Here’s Why Calithera Biosciences Stock Gained as Much as 16.4% Today” with publication date: May 10, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.